Fingerprint
Dive into the research topics where Charles Blanke is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Patel, S. P., Cano-Linson, E., Chae, Y. K., Schokrpur, S., Lao, C. D., Powers, B. C., Victor, A. I., Onitilo, A. A., Shin, S., Takebe, N., Threlkel, S., McLeod, C. M., Chen, H. X., Sharon, E., Othus, M., Ryan, C. W., Blanke, C. D. & Kurzrock, R., Dec 1 2025, In: npj Precision Oncology. 9, 1, 24.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38)
Patel, S. P., Othus, M., Chae, Y. K., Azenkot, T., Wagner, M. J., Threlkel, S., Farley, J. H., Magner, C. M., Chen, H. X., Sharon, E., Ryan, C. W., Blanke, C. & Kurzrock, R., Oct 20 2025, In: Journal for immunotherapy of cancer. 13, 10, e013147.Research output: Contribution to journal › Article › peer-review
Open Access -
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
Battaglin, F., O'Neil, B. H., Stintzing, S., Ou, F. S., Zemla, T. J., Niedzwiecki, D., Innocenti, F., Hochster, H. S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Heintges, T., Lerchenmüller, C., Weiss, L., Heinrich, K., Goldberg, R. M., Mayer, R. J., Schilsky, R. L. & Blanke, C. D. & 3 others, , Sep 9 2025, In: European Journal of Cancer. 227, 115694.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Chae, Y. K., Othus, M., Patel, S. P., Aljumaily, R., Win, K. Z., Pejovic, T., Thomas, S. S., Robinson, W. R., Kim, H. S., Chung, L. I. Y., McLeod, C. M., Chen, H. X., Sharon, E., Streicher, H., Ryan, C. W., Blanke, C. D. & Kurzrock, R., Aug 1 2025, In: Cancer Communications. 45, 8, p. 976-986 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Phase II basket trial of Dual AntiCTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort
Patel, S. P., Fisher, J., Chae, Y. K., Soto, L. S., Kasi, A., Konda, B., Walshauser, M., Parra, E., Zhang, J., Duault, C., Gonzalez-Kozlova, E., Manyam, G., Zhang, J., Chen, H., Duose, D. Y., Fernandez, C. L., Luthra, R., Al-Atrash, G., Kim-Schulze, S. & Maecker, H. T. & 12 others, , Jun 30 2025, In: Journal for immunotherapy of cancer. 13, 6, e011760.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Scopus citations